CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)

NEXT STORY
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
PREV STORY
CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

POINT Biopharma and Bach Biosciences announce licensing and partnership for canSEEK™ pan-cancer targeting technology

author_avatar
NASDAQ Market News

Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer

MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused ...

author_avatar
NASDAQ Market News

Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program

author_avatar
NASDAQ Market News